Relmada Therapeutics to Participate in Jefferies Inaugural Biotech CNS/Neuro Summit

Relmada Therapeutics, a leading biotechnology company focusing on diseases of the central nervous system (CNS), has announced its participation in the Jefferies Inaugural Biotech CNS/Neuro Summit. The event will take place on Thursday, October 12, 2023, in New York, NY.

The summit will feature a fireside chat with Relmada’s CEO, Sergio Traversa, CFO Maged Shenouda, and CMO Cedric O’Gorman. They will also be available for one-on-one investor meetings during the conference.

Relmada Therapeutics is known for its late-stage development of REL-1017, a novel NMDA receptor channel blocker designed to treat major depressive disorder (MDD). The drug targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is being evaluated as a rapid-acting, oral, once-daily antidepressant treatment.

The ongoing clinical research program includes the Relight (Study 304) Phase 3 trial, a randomized, double-blind, placebo-controlled trial, and the Reliance II (Study 302) trial. Both studies aim to assess the potential of REL-1017 as an adjunctive treatment for MDD.

Relmada Therapeutics is dedicated to making a difference in the lives of patients and their families. Their lead program, REL-1017, shows promising potential in addressing the unmet needs of individuals with MDD.

Investors and interested parties can access the webcast of the fireside chat via the Investors section of the Relmada website. The webcast will also be available for replay for 90 days following the event.

Relmada Therapeutics continues to push the boundaries of CNS research and development, bringing hope to those affected by major depressive disorder. To learn more about their innovative approach, visit www.relmada.com.